C. For patients unable to tolerate this dose, lower doses can be used as long as ≥5 percent weight loss is achieved (see 'Dosing' below). Indication. injection in pre-filled pen. Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product. • It is not known if Wegovy™ is safe and effective when taken with other prescription, over-the-counter, or semaglutide (rys) 0. Few episodes (0. Package leaflet: Information for the patient . Use in elderly • Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Indirect comparisons of OW semaglutide vs SGLT-2is on efficacy outcomes have been previously reported, including the systematic literature review and NMA by Sharma et al. In the 259 patients randomised to semaglutide the HbA1c fell by 15. For type 2 diabetics; If switching a patient on to insulin, please ensure an insulin is chosen as per information on the SPS page on prescribing available insulins as not all suppliers are able to manage an uplift in demand. Please ensure to update all your refills, scripts, and any previously saved favorites in the EHR to Ozempic. Last updated on emc: 18 Sep 2023. Semaglutide (4,113. GLP-1 RA. 4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also. 4 mg. 55%) after 30 weeks. Semaglutide. 00 pm on weekdays and bank holidays For more information on diabetes, visit our website If you are feeling unwell or in case of an emergency, please contact your doctor. Novo Nordisk Limited. Inject two inches from the belly button on either side. Pull off both needle caps. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD). Among its multifaceted functions is the ability to connect the absorption of nutrients from the gastrointestinal tract with pancreatic hormone secretion. (semaglutide) is approved and licensed. Disclaimer. In. Important information If you notice severe, persistent abdominal pain, contact your GP. semaglutide This medicine is subject to additional monitoring. It may also be. This will allow quick identification of new safety information. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Contents of the pack and other information . The starting dose is 0. 5 mg, 1 mg, 1. Dapagliflozin. com for more information. Rybelsus® 7 mg tablets . 1). 5 mg, 1 mg, or 2 mg For adult patients with type 2 diabetes (T2D), treated with diet and exercise to improve glycemic control, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2D and established cardiovascular disease. 4 mg solution for injection in pre-filled pen semaglutide. 0mg PIL. Your doctor or nurse will show you how to take it. 4 mg weekly injection of semaglutide plus lifestyle intervention in 1,961 patients with-PATIENT & CAREGIVER EDUCATION Semaglutide This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and. Semaglutide is used to treat type 2 diabetes. The peptide has a low solubility at pH range 2-6. 2 Instructions 17. RYBELSUS ® has not been studied in patients with a history of pancreatitis. (SEMAGLUTIDE TABLETS) This booklet is for patients who have been prescribed RYBELSUS®. In trials of patients with early T2D insufficiently controlled with diet and exercise alone, who had baseline HbA 1c levels of 8. The side effects;In a 2-year cardiovascular outcomes trial with semaglutide injection involving patients with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications (which was a 4 component adjudicated endpoint) occurred in patients treated with semaglutide injection (3. 2). Ozempic 0. wegovy is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. At the start of the study the mean HbA1c was 64. Semaglutide (oral): Patients start with 3 mg by mouth once daily for one month, then increase to 7 mg once daily. 25 mg solution for. Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors (e. With an elimination half-life of approximately 1. . 2. Dapagliflozin. How do GLP-1 analogues work? This type of medication works by increasing the levels of a group of hormones called incretins. Important Safety Information for SEMGLEE (insulin glargine-yfgn injection) pen. If pancreatitis is suspected, Victoza and other potentially suspect drugs should be discontinued. Your doctor may order certain tests to check your body's response to semaglutide. 4 mg once weekly in patients with a BMI of ≥30 kg/m 2 or ≥27 kg/m 2 with more than one weight-related comorbidity. semaglutide . . The text only version may be available in large print, Braille or audio CD . It can also be used as an ‘add-on’ to other diabetes medicines. PATIENT MEDICATION INFORMATION PrWegovy™ semaglutide injection . In the SUSTAIN 1 trial, 388 previously untreated patients were randomised to receive semaglutide (0. Active ingredient(s): semaglutide. Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist). Your doctor may order certain tests to check your body's response to semaglutide. Abstract. This can help with blood glucose levels. • Pancreatitis: In clinical trials, there were more cases of pancreatitis among Victoza-treated patients than among comparator-treated patients. Patients with Early T2D Being Treated With Diet and Exercise. Where to find information in this leaflet: 1. Ozempic helps to regulate appetite and make you feel less hungry by. Ozempic is a product information document that provides detailed information on the medicine semaglutide, which is used to treat type 2 diabetes. org. Ozempic is a prescription medicine that contains semaglutide, a substance that helps lower blood sugar levels in adults with type 2 diabetes. This should come with your order. WEGOVY ® (semaglutide) injection 2. bApplies. Discontinue this medicine if the patient. Ozempic contains the active substance semaglutide. 5 mg/day) will improve the HbA1c level by at least 0. 05 L/h. The most common side-effects are nausea and diarrhoea - these usually reduce over time. This prescription medication works by increasing insulin levels in the body, which decreases blood glucose (sugar). Semaglutide This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call. In trials of patients with early T2D insufficiently controlled with diet and exercise alone, who had baseline HbA 1c levels of 8. Viatris launched a non-interchangeable Semglee in 2020 at a WAC price of $99, marking a steep discount off Lantus' WAC of $284. The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. The authors analyzed published aggregate data and concluded that OW semaglutide 1 mg was significantly more effective than empagliflozin, dapagliflozin, and. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. This medication is injected under the skin. 45–1. Search for information about medicines including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs). Semaglutide injection is used to treat type 2 diabetes. It is a medicine that is used to lower blood sugar levels. Last updated on emc: 18 Sep 2023. 54 mmol/mol (8. org March 18, 2021 991 Semaglutide in Adults with Overweight or Obesity maintenance dose of 2. 4 mg once-weekly dosage, the maintenance dosage may be reduced to 1. Take RYBELSUS ® with a sip of plain water, no more than 4 ounces. CED Journal. The text only version may be available in large print, Braille or audio CD . SGLT2 inhibitors can, in rare cases lead to a. 22 Semaglutide is a GLP-1 receptor agonist (GLP-1RA). 5 MG/DOSE); Ozempic (1 MG/DOSE); Ozempic (2 MG/DOSE); Rybelsus; Wegovy Brand Names: Canada See full list on patient. As experts in compounded medications, we provide custom wellness solutions to satisfy the unique needs of all types of patients. Diabetic Retinopathy Complications: Has been reported in a cardiovascular outcomes trial with semaglutide injection. 5 mg, 1 mg, or 2 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and. Key milestones in the development of subcutaneous semaglutide for the treatment of patients with type 2 diabetes, focussing on phase 3 trials. The text only version may be available in large print, Braille or audio CD. Last updated on emc: 14 Aug. • RYBELSUS is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Check the Ozempic® flow with each new pen. GLP-1 has an important role in controlling appetite. Counsel patients regarding the potential risk of MTC and symptoms of thyroidWegovy is available as pre-filled pens containing a solution for injection. Ozempic can be used on its own in patients who cannot take metformin (another diabetes medicine). Resources for Canadian patients. Ozempic is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled. Semaglutide is a GLP-1 agonist and works by increasing insulin release, lowering the. This Patient Information has been approved by the U. 5mg WEEKLY for at least 4 weeks or maintenance 1 Box of 1 Pen semaglutide(8. To reduce the risk of symptoms affecting the gut, the weekly dose is gradually increased over 16 weeks. The product code(s) for this leaflet is: PLGB 04668/0332. Semaglutide is a glucagon-like peptide-1 (GLP-1. S. 2 Pharmacokinetic Properties). Download a digital Patient Starter Kit. lixisenatide and semaglutide • SGLT2 inhibitors – dehydration can make it more likely that you will develop a serious side effect called ketoacidosis. • OZEMPIC ® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2. Patients should take RYBELSUS ® with a sip of plain water. Attach a new needle. Last updated on emc: 18 Sep 2023. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes. How and when to take it. Store unopened packs of liraglutide in a fridge. Resources for Canadian patients. Print patient leaflet as text only. GLP-1’s (incretin mimetics) There are six medications in the incretin mimetic/GLP-1 analogues family. The product code (s) for this leaflet is: PLGB 04668/0333. 1. Cardiovascular Outcomes Trial of Semaglutide 0. Consumer Medicine Information (CMI) This leaflet provides important information about using Ozempic ®. Possible side effects . Counsel patients regarding5. For patients considered overweight or with obesity, we treat with semaglutide injections at the maximum dose (2. But as interest in semaglutide for weight loss continues to grow, health care professionals are finding ways to manage the demand. What is semaglutide? Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP. 19, 95%CI [1. Clearance of semaglutide in patients with type 2 diabetes was approximately 0. Rybelsus is a medication that is used to lower blood sugar levels in type 2 diabetes patients and also a medication that can help with weight loss. It explains how to use wegovy, what to watch out for, and what to do if you have any side effects or questions. One of the 17 patients who received oral semaglutide treatment was lost to follow‐up (non‐adherence). 1). Discontinue promptly if pancreatitis is suspected. With an elimination half-life of approximately 1. uk | +44 (0)020 7383 0266More participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77. 1, 13. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. For chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI ≥30 kg/m 2 (obesity), or ≥27 kg/m 2 (overweight) in the presence of a weight-related comorbidity, and for pediatric patients aged 12 years and older with an initial BMI at ≥95. Swallow the tablets whole, do not cut, crush, or chew. RYBELSUS ® (semaglutide) tablets 7 mg or 14 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Many prescribe other brands of semaglutide, such as Ozempic and Rybelsus, off-label (using. Company contact pointside effects not listed in this leaflet. Changes to the PIL after your medicine was packed may mean that the version on. In rodents, semaglutide causes thyroid C-cell tumors. It has been approved as a second line treatment option for better glycaemic control in type 2 diabetes and currently under scrutiny for anti-obesity. The typical dose for weight loss is 2. B. Subcutaneous (SC) semaglutide (Ozempic®) is a GLP-1RA with an extended half-life of approximately 1. semaglutide of variable doses ranging from 0. 1 , 2 The efficacy and safety response to a diabetes therapy may vary according to patient characteristics, such as age, body mass index (BMI) and. 1 Semaglutide (Wegovy, Novo Nordisk) is ‘indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight Liraglutide for diabetes. Cases of MTC in patients treated with liraglutide, another GLP-1. wegovy® 0. What do I need to tell my doctor BEFORE I take Semaglutide Tablets? If you are. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. † Regulations require you to enter your drug identification number (DIN) to access content that is intended only for patients who have been prescribed Ozempic ® . For these groups, semaglutide is recommended alongside intensive weight management in an appropriate multidisciplinary setting. 0 kg/m 2 to 34. uk. Revised: 9/2023 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: RISK OF THYROID C−CELL TUMORS. 9% for placebo group. 4 mg. Package leaflet: Information for the patient. Weight Management Study in Pediatric Patients Aged 12 Years and Older with Obesity 14. 4 mg injected subcutaneously once weekly. Ozempic ® (semaglutide) injection 0. To date, the most. bApplies to eligible, commercially insured patients with coverage unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product. 96 mmol/mol (1. 5 mg or 1 mg is an injectable prescription medicine used: • along with diet and exercise to improve blood sugar in adults with type 2. According to Caroline Messer, MD, a board-certified. 25 or 0. Indications and Usage. 5 mg and 1 mg in Adult Patients with Type 2 Diabetes and Cardiovascular Disease . to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known. solution for injection in pre-filled pen. 1). Administered via injection, GLP-1 RAs work by mimicking the effects of the hormone GLP-1 produced in the body when eating, stimulating the pancreas to secrete insulin and reduce blood glucose levels. You can help by reporting any side effects you may get. a Eligible, commercially insured patients only. The MHRA products website allows you to find: The leaflets which are provided with medicines. 9–16. 3). 4 mg solution for injection in pre-filled pen semaglutide This medicine is subject to additional monitoring. Message frequency will be based on your selections. See the end of. Please see the Patient Information Leaflet for full information. Dose counter. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. This will allow quick identification of new safety information. The description of the medicinal product’s properties and how it can be used. 6 Hypoglycemia in Patients with Type 2 Diabetes Mellitus on Anti-Diabetic Therapy 17. 56 Patients with T2D and upper GI disease (chronic gastritis [n = 5], gastroesophageal reflux disease [n = 8], or both [n = 23]) or without upper GI disease (n. Dose pointer. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). For chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI ≥30 kg/m 2 (obesity), or ≥27 kg/m 2 (overweight) in the presence of a weight-related comorbidity, and for pediatric patients aged 12 years and older with an initial BMI at ≥95. In patients with diabetic retinopathy treated with insulin and s. 9%, and 43. 8 and 4. 4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also Rybelsus® (semaglutide tablets) Product Monograph Page 33 of 39 PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PRRYBELSUS® semaglutide tablets Read this carefully before you start taking Rybelsus® and each time you get a refill. wegovy FlexTouch. Gastrointestinal adverse reactions. S. Package leaflet: Information for the patient wegovy FlexTouch 0. The information for each product comes in the form of a Summary of Product Characteristics (SPC or SmPC) and Patient Information Leaflet (PIL) or Package Leaflet (PL), where relevant. 5 mg dose, 2 mg/3 mL (subcutaneous solution, 1 pen) as soon as it is available for selection in the EHR, starting in March 2023. Following at least 30 days at a dosage of 7 mg once daily, the dose can be further increased to 14 mg if additional glycemic control is required ( Figure 2 ). This will allow quick identification of new safety information. Turn the dose selector until the dose counter shows the flow check symbol. Wait 30 minutes before the first food, beverage, or other oral medications of the day. Changes to the PIL after your medicine was packed may mean. However, diastolic blood. Support patients to access structured education and weight management programmes where available. Take it as directed on the prescription label. It also said patients should be urged to check the patient information leaflets for each product to clarify what genuine pens look like. 3. 5 mg once weekly. Findings In this cohort study of 175 patients with overweight or obesity, the total body weight loss percentages achieved were 5. Children younger than 12 years of age—Use and dose must be determined by your doctor. For more information, see Section . Please always ensure that you read the patient information leaflet. 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. In rodents, semaglutide causes thyroid C-cell tumors. Semaglutide is highly efficacious, with the majority of patients experiencing clinically significant weight. 05%). Last updated on. Risk of Thyroid C-cell Tumors. Patient leaflet and Counselling check list Semaglutide —Ozempic® At your appointment today we have agreed to start treatment with a WEEKLY injectable medicine to help manage your type 2 diabetes. Semaglutide is a longer-acting GLP-1 receptor agonist compared with Liraglutide, this is why it doesn't need to be injected as often. Controlling high blood sugar. Clearance of semaglutide in patients with type 2 diabetes was approximately 0. , a mass in the neck, dysphagia, dyspnea, persistent hoarseness). 7 mg and 2. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. These hormones are released throughout the day and levels are. Ozempic is referred to generically as a 'semaglutide injection'. 36,3. Liraglutide (also called Saxenda) and semaglutide (also called Wegovy) are weight loss medicines that work by making you feel fuller and less hungry. † Regulations require you to enter your drug identification number (DIN) to access content that is intended only for patients who have been prescribed Ozempic ® . to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease. manufacturer), and the specific batch -number. The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. Consider other antidiabetic therapies in patients with a history of. 0–8. The text only version may be available in large. 9–16. For these groups, semaglutide is recommended alongside intensive weight management in an appropriate multidisciplinary setting. 73 m 2, with few hypoglycemic episodes . 2 Pharmacokinetic Properties). Text HELP to 21848 for help. How and when to take it. The product code (s) for this leaflet is: 44490/0003. Ozempic 1 mg solution for injection in pre-filled pen . Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with semaglutide tablets and each time you refill your prescription. Indications and Limitations of Use. • Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Do ensure that you have read the patient information leaflet to be fully aware of the all the side effects. 8 mg without dose escalation, or doses of 0. Patient Information Leaflet: For more information on the medication please refer to the patient information leaflet for Wegovy. For the other patients, no changes in antidiabetic or anti‐dyslipidemic medications including dosage were made during the observation period (Table S1, Supporting information). Gently pull the syringe out of the skin. It is injected once a week under the skin in the belly, thigh or upper arm. healthdirect medicines information is not intended for use in an emergency. This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. 9%) in the placebo group (hazard ratio, 0. The CV outcomes trial PIONEER 6 evaluated CV safety of oral semaglutide in 3,183 patients at high CV risk (aged ≥50 years with established CVD or CKD, or aged ≥60 years with CV risk factors only) . 8 mg doses of daily-once liraglutide, or placebo. 3 Risk of Thyroid C-cell Tumors 17. It explains how to use wegovy, what to watch out for, and. Other information about Wegovy Wegovy received a marketing authorisation valid throughout the EU on 6 January 2022. 101-2476 Argentia Road. Includes indications, proper use, special instructions, precautions, and possible side effects. Wegovy™ (semaglutide) injection 2. If you are worried about using this medicine, speak to your doctor or pharmacist. Ozempic ® (semaglutide) injection 0. The clearance of semaglutide in patients with overweight (BMI ≥27 kg/m 2 to <30 kg/m 2) or obesity (BMI ≥ 30 kg/m 2) was approximately 0. Wegovy ® (semaglutide) injection 2. You can help by reporting any side effects you may get. The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. This medicine is also used to lower the risk of heart attack, stroke, or death in patients with type 2 diabetes and heart or blood vessel disease. Please see the Patient Information Leaflet for full information. 7 mg and 2. Patients with Early T2D Being Treated With Diet and Exercise. 1-844-TLR-MADE; 1 (859) 887 0013; support@tailormadecompounding. It is unknown whether RYBELSUS causes thyroid C-cell. A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine packaging. 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION17 PATIENT COUNSELING INFORMATION 17. Licence Holder Novo Nordisk A/S. along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes. Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs HCP Med Info. Subcutaneous semaglutide 2·4 mg taken once per week is a glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of obesity on the basis of the findings of the global phase 3 STEP programme, which demonstrated bodyweight reductions of 14·9–17·4% on average in people with overweight or obesity, without type 2 diabetes,. 8%). Consult the Patient Information Leaflet for a comprehensive list of ingredients. The most common adverse effect of semaglutide is an increase in heart rate, with an increase of 10 to 19 beats per minute in 41% of patients (34% with placebo) and 20 beats per minute in 26% of. 4 How do I use my Ozempic® pen? This is a Quick Guide. Indications and Usage. 7 mg once weekly. The global shortage in supply is partly due to a surge in off label prescriptions of the drug semaglutide being issued for weight loss which is outstripping. 4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adults with an initial body mass index (BMI) of ≥30 kg/m 2 (obesity) or ≥27 kg/m 2 (overweight) in the presence of at least one weight-related comorbid. to reduce the risk of major. Serious and life-threatening cases of diabetic ketoacidosis have been reported in patients with type 2 diabetes mellitus on a combination of insulin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide, liraglutide. Additionally, when providing patients with details of the vaccine or biological medicine administered, it is good practice to give them details of the brand and batch number. Read this Medication Guide and Instructions for Use before you start using WEGOVY and each time you get a refill. lichen-planus. Liraglutide is taken once a day, and semaglutide is taken once a week. Press and hold in the dose button until the dose counter shows 0. This includes any possible side effects not listed in the package leaflet. 4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adults with an initial body mass index (BMI) of ≥30 kg/m 2 (obesity) or ≥27 kg/m 2 (overweight) in the presence of at least one weight-related comorbid. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with. Follow all instructions closely. Below is a text only representation of the Patient Information Leaflet (ePIL). Ozempic. How to use Saxenda® 4. However the dose is usually not more than 2. Ozempic is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled. The recommended maintenance dosage of Wegovy is 2. Results of STEP 1-4 were published this spring: STEP 1 tested a 2. 5 or 1. 0%) compared to placebo (1. The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. This will allow quick identification of new safety information. 1007/s13300-023-01506-1. Wegovy® (semaglutide) injection 2. 5 mg, 1 mg, or 2 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and e. Below is a text only representation of the Patient Information Leaflet (ePIL). These are not all the possible side effects of. 6 November 2013. 8, 1. 5 mg or 1 mg is an. Please see additional Important Safety Information throughout. Drug and dose Quantity to prescribe for 4 weeks Semaglutide 0.